08:43 AM EST, 02/26/2025 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Wednesday that the US Food and Drug Administration has accepted its supplemental new drug application for Zoryve to treat mild to moderate atopic dermatitis in children two to five years old.

The medical dermatology company said the FDA has set a Prescription Drug User Fee Act target action date of Oct. 13.

Shares of Arcutis Biotherapeutics ( ARQT ) were up almost 9% in recent premarket activity.